Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS. Nguyen AN, et al. Among authors: protter a. Exp Cell Res. 2006 Jun 10;312(10):1909-23. doi: 10.1016/j.yexcr.2006.02.026. Epub 2006 Apr 4. Exp Cell Res. 2006. PMID: 16600214
A selective p38 alpha mitogen-activated protein kinase inhibitor reverses cartilage and bone destruction in mice with collagen-induced arthritis.
Medicherla S, Ma JY, Mangadu R, Jiang Y, Zhao JJ, Almirez R, Kerr I, Stebbins EG, O'Young G, Kapoun AM, Luedtke G, Chakravarty S, Dugar S, Genant HK, Protter AA. Medicherla S, et al. Among authors: protter aa. J Pharmacol Exp Ther. 2006 Jul;318(1):132-41. doi: 10.1124/jpet.105.098020. Epub 2006 Apr 5. J Pharmacol Exp Ther. 2006. PMID: 16597712
Preventive and therapeutic potential of p38 alpha-selective mitogen-activated protein kinase inhibitor in nonobese diabetic mice with type 1 diabetes.
Medicherla S, Protter AA, Ma JY, Mangadu R, Almirez R, Koppelman B, Kerr I, Navas TA, Movius F, Reddy M, Liu YW, Luedtke G, Perumattam J, Mavunkel B, Dugar S, Schreiner GF. Medicherla S, et al. Among authors: protter aa. J Pharmacol Exp Ther. 2006 Jul;318(1):99-107. doi: 10.1124/jpet.105.097857. Epub 2006 Apr 7. J Pharmacol Exp Ther. 2006. PMID: 16603672
Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS. Navas TA, et al. Among authors: protter aa. Leukemia. 2006 Jun;20(6):1017-27. doi: 10.1038/sj.leu.2404200. Leukemia. 2006. PMID: 16617327
B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation.
Kapoun AM, Liang F, O'Young G, Damm DL, Quon D, White RT, Munson K, Lam A, Schreiner GF, Protter AA. Kapoun AM, et al. Among authors: protter aa. Circ Res. 2004 Mar 5;94(4):453-61. doi: 10.1161/01.RES.0000117070.86556.9F. Epub 2004 Jan 15. Circ Res. 2004. PMID: 14726474
89 results